Literature DB >> 3522353

Dopamine receptors in normal and diabetic liver plasma membrane.

C F Nassar, E G Karkaji, Z M Habbal, M G Nasser.   

Abstract

Dopamine binding to liver plasma membrane isolated from diabetic livers was significantly reduced (P less than 0.01) as compared to dopamine binding to the normal membrane. Diabetic membranes exhibited a significant decrease (P less than 0.01) in specific dopamine binding as compared to the normal membranes; whereas no significant change (P less than 0.5) was noticed in the nonspecific binding patterns. The dopamine binding capacity of both membranes is temperature dependent. Procaine at different concentrations inhibited significantly (P less than 0.01) dopamine binding to normal and diabetic membranes. Treatment of the normal and diabetic membranes with insulin showed a 33% decrease in the binding capacity of the normal and 42% decrease in the binding capacity of the diabetic membrane.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522353     DOI: 10.1016/0306-3623(86)90057-1

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  3 in total

1.  A small-molecule screen reveals that HSP90β promotes the conversion of induced pluripotent stem cell-derived endoderm to a hepatic fate and regulates HNF4A turnover.

Authors:  Ran Jing; Cameron B Duncan; Stephen A Duncan
Journal:  Development       Date:  2017-03-30       Impact factor: 6.868

2.  Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells.

Authors:  Jiao-Jiao Xu; Si-Yuan Wang; Ye Chen; Guang-Ping Chen; Zai-Quan Li; Xue-Yan Shao; Liang Li; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

3.  Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance.

Authors:  Elodie M Girault; Anneke Alkemade; Ewout Foppen; Mariëtte T Ackermans; Eric Fliers; Andries Kalsbeek
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.